BlackRock
FULC icon

BlackRock’s Fulcrum Therapeutics FULC Stock Holding History

BlackRock’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3M Buy
8,824,259
+3,433,666
+64% +$20.9M ﹤0.01% 2950
2026
Q1 		$41.3M Buy
5,390,593
+1,126,832
+26% +$10.5M ﹤0.01% 2629
2025
Q4 		$48.2M Buy
4,263,761
+557,011
+15% +$5.67M ﹤0.01% 2536
2025
Q3 		$34.1M Sell
3,706,750
-672,273
-15% -$4.86M ﹤0.01% 2755
2025
Q2 		$30.1M Sell
4,379,023
-331,674
-7% -$1.77M ﹤0.01% 2783
2025
Q1 		$13.6M Sell
4,710,697
-458,732
-9% -$1.69M ﹤0.01% 3155
2024
Q4 		$24.3M Sell
5,169,429
-537,098
-9% -$1.98M ﹤0.01% 2920
2024
Q3 		$20.4M Buy
5,706,527
+908,005
+19% +$6.74M ﹤0.01% 3031
2024
Q2 		$29.8M Buy
4,798,522
+3,257,313
+211% +$24.7M ﹤0.01% 2741
2024
Q1 		$14.5M Sell
1,541,209
-20,657
-1% -$184K ﹤0.01% 3160
2023
Q4 		$10.5M Buy
1,561,866
+115,928
+8% +$514K ﹤0.01% 3372
2023
Q3 		$6.42M Sell
1,445,938
-68,487
-5% -$299K ﹤0.01% 3558
2023
Q2 		$5M Sell
1,514,425
-2,669,313
-64% -$7.84M ﹤0.01% 3731
2023
Q1 		$11.9M Buy
4,183,738
+914,747
+28% +$8.2M ﹤0.01% 3226
2022
Q4 		$23.8M Buy
3,268,991
+496,647
+18% +$3.24M ﹤0.01% 2932
2022
Q3 		$22.4M Buy
2,772,344
+117,966
+4% +$845K ﹤0.01% 2972
2022
Q2 		$13M Buy
2,654,378
+425,768
+19% +$4.16M ﹤0.01% 3357
2022
Q1 		$52.7M Buy
2,228,610
+20,532
+0.9% +$291K ﹤0.01% 2552
2021
Q4 		$39.1M Buy
2,208,078
+177,205
+9% +$3.51M ﹤0.01% 2824
2021
Q3 		$57.3M Buy
2,030,873
+733,428
+57% +$13.9M ﹤0.01% 2575
2021
Q2 		$13.6M Buy
1,297,445
+168,866
+15% +$1.71M ﹤0.01% 3527
2021
Q1 		$13.3M Buy
1,128,579
+85,295
+8% +$1.05M ﹤0.01% 3419
2020
Q4 		$12.2M Buy
1,043,284
+384,087
+58% +$4.34M ﹤0.01% 3268
2020
Q3 		$5.23M Sell
659,197
-11,155
-2% -$134K ﹤0.01% 3559
2020
Q2 		$12.3M Buy
670,352
+49,287
+8% +$776K ﹤0.01% 3071
2020
Q1 		$7.42M Buy
621,065
+410,689
+195% +$6.57M ﹤0.01% 3149
2019
Q4 		$3.5M Buy
210,376
+115,776
+122% +$1.11M ﹤0.01% 3607
2019
Q3 		$628K Buy
+94,600
New +$1.05M ﹤0.01% 4112

Other funds holding FULC

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock's FULC Position: Q2 2026 in Review

BlackRock increased its Fulcrum Therapeutics (FULC) stake by 64% in Q2 2026, buying an estimated $20.9M and bringing the position to 8,824,259 shares worth $32.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2950.

BlackRock first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $57.3M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • BlackRock held 8,824,259 shares of Fulcrum Therapeutics worth $32.3M as of Q2 2026.
  • BlackRock bought 3,433,666 Fulcrum Therapeutics shares in Q2 2026, an estimated $20.9M.
  • Fulcrum Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2950 holding.
  • BlackRock first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • BlackRock's Fulcrum Therapeutics position peaked at $57.3M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.